Molecular alterations in pancreatic and periampullary cancers;Molekulare veranderungen bei pankreasund periampullaren karzinomen

Chirurgische Gastroenterologie mit Interdisziplinaren Gesprachen

Volumn 15, Issue 2, 1999, Pages 150-157

  Friess, H ^a   Kleeff, J ^a   Klockow, N ^b   Ebert, M ^b   Malfertheiner, P ^b   Buchler M W ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Gene mutations; Growth factor receptors; Growth factors; Pancreatic cancer; Periampullary cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

CARCINOGENESIS; GENE MUTATION; GENE OVEREXPRESSION; METASTASIS; MOLECULAR GENETICS; ONCOGENE; ONCOGENE K RAS; PANCREAS CANCER; PROTEIN EXPRESSION; REVIEW; TUMOR GROWTH; VATER PAPILLA TUMOR;

EID: 0032773044     PISSN: 01779990     EISSN: None     Source Type: Journal    
DOI: 10.1159/000012547     Document Type: Review

References (99)

1. Friess H, Büchler M, Beglinger C, Krüger M, Beger HG: Low-dose octreotide treatment is not effective in patients with advanced pancreatic cancer. Pancreas 1993;8:540-544.
2. National Cancer Institute: Annual cancer statistics review 1973-1988. Bethesda, Md, Department of Health and Human Services, 1991 (NIH publication no. 91-2789).
3. Silverberg E, Lubera JA: Cancer statistics. Cancer J Clin 1989;3:3-39.
4. Warshaw AL, Fernandes-Del Castillo C: Pancreatic carcinoma. N Engl J Med 1992;326:455-465.
5. Poen JC, Ford JM, Niederhuber JE: Chemoradiotherapy in the management of localized tumors of the pancreas. Ann Surg Oncol 1999;6:117-122.
6. White R, Lee C, Anscher M, Gottfried M, Wolff R, Keogan M, Pappas T, Hurwitz H, Tyler D: Preoperative chemoradiation for patients with locally advanced adenocarcinoma of the pancreas. Ann Surg Oncol 1999;6:38-45.
7. Evans DB, Abbruzzese JL: Chemoradiation for localized pancreatic cancer: Another perspective. Ann Surg Oncol 1999;6:4-7.
8. Moertel CG, Childs DS, Reitemeier RJ, Colby MY, Holbrook M: Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 1969;ii:865-900.
9. Neoptolemos JP (ed): Cancer of the pancreas. Baillieres Clinical Gastroenterology, London, 1990.
10. Andrén-Sandberg A: Treatment with an LHRH analogue in patients with advanced pancreatic cancer. Acta Chir Scand 1990;156:549-551.
11. Büchler M, Friess H, Schultheiss KH, Gebhardt Ch, Kübel R, Muhrer KH, Winkelmann M, Wagener T, Klapdor R, Kaul M, Müller G, Schulz G, Beger HG: A randomized controlled trial of adjuvant immunotherapy (murine monoclonal antibody 494/32) in resectable pancreatic cancer. Cancer 1991;68:1507-1512.
12. Friess H, Büchler M, Schulz G, Beger HG: Therapie des Pankreaskarzinoms mit dem monoklonalen Antikörper BW 494/32: Erste klinische Ergebnisse. Immun Infekt 1989;17:24-26.
13. Friess H, Büchler M, Krüger M, Beger HG: Treatment of duct carcinoma of the pancreas with the LH-RH analogue buserelin. Pancreas 1992:7;516-521.
14. Glinsmann-Gibson BJ, Korc M: Regulation of transforming growth factor-alpha mRNA expression in T3M4 human pancreatic carcinoma cells. Pancreas 1991;6:142-149.
15. Korc M, Meltzer P, Trent J: Enhanced expression of epidermal growth factor receptor correlates with alterations of chromosome 7 in human pancreatic cancer. Proc Natl Acad Sci USA 1986;83:5141-5144.
16. Korc M, Finman JE: Attenuated processing of epidermal growth factor in the face of marked degradation of transforming growth factor alpha. J Biol Chem 1989;264:14990-14999.
17. Coussens L, Yank-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985;230:1132-1139.
18. Kraus MH, Issing W, Miki T, Popescu NC, Aaronson SA: Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: Evidence for overexpression in a subset of human mammary tumors. Proc Natl Acad Sci USA 1989;86:9193-9197.
19. Plowman GD, Culouscou JM, Whitney GS, Green JM, Carlton GW, Foy L, Neubauer MG, Shoyab M: Ligand specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci USA 1993;90:1746-1750.
20. Schlessinger J, Ullrich A: Growth factor signaling by receptor tyrosine kinases. Neuron 1992; 9:383-391.
21. Toyoda H, Komurasaki T, Uchida D, Takayama Y, Isobe T, Okuyama T, Hanada K: Epiregulin. A novel epidermal growth factor with mitogenic activity for rat primary hepatocytes. J Biol Chem 1995;270:7495-7500.
22. Holmes WE, Sliwkowski MX, Akita RW: Identification of heregulin, a specific activator of p185erbB2. Science 1992;256:1205-1210.
23. Barton CM, Hall PA, Hughes CM, Gullick WJ, Lemoine NR: Transforming growth factor alpha and epidermal growth factor in human pancreatic cancer. J Pathol 1991;163;111-116.
24. Ciccodicola A, Dono R, Obici S, Simeone A, Zollo M, Persico MG: Molecular characterization of a gene of the 'EGF family' expressed in undifferentiated human NTERA2 teratocarcinoma cells. EMBO J 1989;8:1987-1991.
25. Higashiyama S, Abraham JA, Miller J, Fiddes JC, Klagsbrun M: A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science 1991;251:936-939.
26. Plowman GD, Green JM, McDonald VL, Neubauer MG, Disteche CM, Todaro GJ, Shoyab M: The amphiregulin gene encodes a novel epidermal growth factor-related protein with tumor-inhibitory activity. Mol Cell Biol 1981;10:1969-1981.
27. Aaronson SA: Growth factors and cancer. Science 1991;254;1146-1153.
28. Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, Soreq H, Whittle N, Waterfield MD, Ullrich A, Schlessinger J: Amplification, enhanced expression, and possible rearrangement of the EGF receptor gene in primary human brain tumors of glial origin. Nature 1985;313:144-147.
29. Korc M, Chandrasekar B, Yamanaka Y, Friess H, Büchler M, Beger HG: Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increase in the levels of epidermal growth factor and transforming growth factor alpha. J. Clin. Invest 1992;90:1352-1360.
30. Yamanaka Y, Friess H, Kobrin MS, Büchler M, Beger HG, Korc M: Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 1993; 13:565-570.
31. Shing Y, Christofori D, Hanahan D, Ono Y, Sasada R, Igarashi K, Folkman J: Betacellulin: A mitogen from pancreatic b cell tumors. Science 1993;259:1604-1607.
32. Yokoyama M, Funatomi H, Kobrin MS, Ebert M, Friess H, Büchler MW, Korc M: Beta-cellulin, a member of the epidermal growth factor family, is overexpressed in human pancreatic cancer. Int J Oncol 1995;7:825-829.
33. Ebert M, Yokoyama M, Kobrin MS, Friess H, Lopez M, Büchler MW, Johnson GR, Korc M: Induction and expression of amphiregulin in human pancreatic cancer. Cancer Res 1994; 54:3959-3962.
34. Yokoyama M, Ebert M, Funatomi H, Friess H, Büchler MW, Johnson GR, Korc M: Amphiregulin is a potent mitogen in human pancreatic cancer cells: Correlation with patient survival. Int J Oncol 1995;6:625-631.
35. Yokoyama M, Funatomi H, Hope C, Damm D, Friess H, Büchler MW, Abraham J, Korc M: Heparin-binding EGF-like growth factor expression and biological action in human pancreatic cancer cells. Int J Onc 1996;8:289-295.
36. Hall PA, Hughes CM, Staddon SL, Richman PI, Gullick WJ, Lemoine NR: The c-erbB-2 protooncogene in human pancreatic cancer. J Pathol 1990;161:1995-2000.
37. Yamanaka Y, Friess H, Kobrin MS, Büchler M, Kunz J, Beger HG, Korc M: Overexpression of HER2/neu oncogene in human pancreatic cancer. Hum Pathol 1993;24:1127-1134.
38. Peles E, Ben-Levy R, Tzahar E, Liu N, Wen D, Yarden Y: Cell-type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/Her-2 suggests complex ligand-receptor relationships. EMBO J 1993;12:961-971.
39. Lemoine NR, Lobresco M, Leung H, Barton C, Hughes CM, Prigent SA, Gullick WJ, Klöppel G: The erbB-3 gene in human pancreatic cancer. J Pathol 1992;168:269-273.
40. Friess H, Yamanaka Y, Kobrin MS, Do AD, Büchler MW, Korc M: Enhanced erbB-3 expression in human pancreatic cancer correlates with tumor progression. Clin Cancer Res 1995;1:1413-1420.
41. Graber HU, Friess H, Kaufmann B, Willi D, Zimmermann A, Korc M, Büchler MW: erbB-4 mRNA expression is decreased in non-metastatic pancreatic cancer. Int J Cancer 1999;84:24-27.
42. Funatomi H, Itakura J, Ishiwata T, Pastan I, Thompson SA, Johnson GR, Korc M: Amphiregulin antisense oligonucleotide inhibits the growth of T3M4 human pancreatic cancer cells and sensitizes the cells to EGF receptor-targeted therapy. Int J Cancer 1997;72:512-517.
43. Wagner M, Cao T, Lopez ME, Hope C, van Nostrand K, Kobrin MS, Fan HU, Buchler MW, Korc M: Expression of a truncated EGF receptor is associated with inhibition of pancreatic cancer cell growth and enhanced sensitivity to cisplatinum. Int J Cancer 1996;68:782-787.
44. Bouche G, Gas N, Prats H, Baldin V, Tauber JP, Teissie J, Amalrie F: Basic fibroblast growth factor enters the nucleus and stimulates the transcription of ribosomal genes in ABAE cells undergoing G0-G1 transition. Proc Natl Acad Sci USA 1987;84:6770-6774.
45. Folkman J, Klagsbrun M: Angiogenic factors. Science 1987;235:442-447.
46. Gospoderowicz D, Neufeld G, Schweigerer L: Molecular and biological characterization of fibroblast growth factor, an angiogenic factor which also controls the proliferation and differentiation of mesoderm and neuroectoderm derived cells. Cell Diff 1986;19:1-17.
47. Gospoderowicz D, Ferrara N, Schweigerer L, Neufeld G: Structural characterization and biological functions of fibroblast growth factor. Endocrine Rev 1987;8:95-114.
48. Klagsbrun M: The fibroblast growth factor family: Structural and biological properties. Prog Growth Factor Res 1989;1:207-235.
49. Kobrin MS, Yamanaka Y, Friess H, Lopez ME, Korc M: Aberrant expression of the type I fibroblast growth factor receptor in human pancreatic adenocarcinomas. Cancer Res 1993;53:4741-4744.
50. Kleeff J, Ishiwata T, Kumbasar A, Friess H, Büchler MW, Lander A, Korc M: The cell-surface heparan sulfate proteoglycan glypican-1 is an important regulator of growth factor action in pancreatic carcinoma cells, and is overexpressed in human pancreatic cancer. J Clin Invest 1998;102:1662-1673.
51. Friess H, Kobrin MS, Korc M: Acidic and basic fibroblast growth factors and their receptors are expressed in the human pancreas (abstract). Pancreas 1992;7:737.
52. Kornmann M, Beger HG, Korc M: Role of fibroblast growth factors and their receptors in pancreatic cancer and chronic pancreatitis. Pancreas 1998;17:169-175.
53. Yamanaka Y, Friess H, Büchler M, Beger HG, Uchida E, Onda M, Kobrin MS, Korc M: Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage. Cancer Res 1993;53:5289-5296.
54. Kornmann M, Ishiwata T, Beger HG, Korc M: Fibroblast growth factor-5 stimulates mitogenic signaling and is overexpressed in human pancreatic cancer: Evidence for autocrine and paracrine actions. Oncogene 1997;15:1417-1424.
55. Bellosta P, Talarico D, Rogers D, Basilico C: Cleavage of K-FGF produces a truncated molecule with increased biological activity and receptor binding affinity. J Cell Biol 1993;121:705-713.
56. Sidiqi I, Funatomi H, Kobrin MS, Friess H, Büchler MW, Korc M: Increased expression of keratinocyte growth factor in human pancreatic cancer. Biochem Biophys Res Commun 1995;215:309-315.
57. Ishiwata T, Friess H, Büchler MW, Lopez ME, Korc M: Characterization of keratinocyte growth factor and receptor expression in human pancreatic cancer. Am J Pathol 1998;153:213-222.
58. Westermark B, Heldin CH: Platelet-derived growth factor in autocrine transformation. Cancer Res 1991;51:5087-5092.
59. Ebert M, Yokoyama M, Friess H, Kobrin MS, Büchler MW, Korc M: Induction of platelet-derived growth factor A and B chains and overexpression of their receptors in human pancreatic cancer. Int J Cancer 1995;62:529-535.
60. Massague J: TGF-beta signal transduction. Annu Rev Biochem 1998;67:753-791.
61. Massague J, Cheifetz S, Laiho M, Ralph DA, Weiss FMB, Zentella A: Transforming growth factor-beta: Cancer Surv 1992;12:81-103.
62. Roberts AB, Sporn MG, Assoian RK, Smith JM, Roche NS: Transforming growth factor type-b: Rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 1986;83:4167-4171.
63. Sporn MB, Roberts AB: Transforming growth factor-β: Recent progress and new challenges. J Cell Biol 1992;119:1017-1021.
64. Friess H, Yamanaka Y, Büchler M, Ebert M, Beger HG, Gold LI, Korc M: Enhanced expression of transforming growth factor-beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 1993;105:1846-1856.
65. Friess H, Yamanaka Y, Büchler M, Beger HG, Kobrin MS, Baldwin RL, Korc M: Enhanced expression of the type II transforming growth factor-beta receptor in human pancreatic cancer cells without alteration of type III receptor expression. Cancer Res 1993;53:2704-2707.
66. Baldwin RL, Friess H, Yokohama M, Lopez ME, Kobrin MS, Büchler MW, Korc M: Attenuated ALK5 receptor expression in human pancreatic cancer: Correlation with resistance to growth inhibition. Int J Cancer 1992;67:283-288.
67. Kleeff J, Wildi S, Friess H, Korc M: Ligand induced up-regulation of the type II transforming growth factor TGF-β receptor enhances TGF-β-responsiveness in COLO-357 cells. Pancreas 1999 (in press).
68. Schutte M, Hruban RH, Hedrick L, Cho KR, Nadasdy GM, Weinstein CL, Bova GS: DPC4 gene in various tumor types. Cancer Res 1996;56:2527-2530.
69. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE: DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996;271: 350-353.
70. Grau AM, Zhang L, Wang W, Evans DB, Abbruzzese JL, Zhang W, Chiao PJ: Induction of p21waf1 expression and growth inhibition by transforming factor beta involve the tumor suppressor gene DPC4 in human pancreatic adenocarcinoma cells. Cancer Res 1997;57:3929-3934.
71. Wagner M, Kleeff J, Lopez ME, Bockmann I, Massague J, Korc M: Transfection of the type I TGF-beta receptor restores TGF-beta responsiveness in pancreatic cancer. Int J Cancer 1998;78:255-260.
72. Kleeff J, Maruyama H, Friess H, Büchler MW, Falb D, Korc M: Smad6 suppresses TGF-β induced growth inhibition in COLO-357 pancreatic cancer cells, and is over-expressed in pancreatic cancer. Biochem Biophys Res Com 1999;255:268-273.
73. Kleeff J, Ishiwata T, Friess H, Büchler MW, Korc M: Concomitant overexpression of activin/inhibin beta subunits and their receptors in human pancreatic cancer. Int J Cancer 1998; 11:860-868.
74. Kleeff J, Maruyama H, Ishiwata T, Sawhney H, Friess H, Büchler MW, Korc M: Bone morphogenetic protein-2 exerts diverse effects on cell growth in vitro, and is expressed in human pancreatic cancer in vivo. Gastroenterology 1999 (in press).
75. Levine A: The p53 tumour suppressor gene and product. Cancer Surv 1992;12:59-79.
76. Vogelstein B, Kinzler KW: p53 function and dysfunction. Cell 1992;70:523-526.
77. Hollenstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 1991;253:49-53.
78. Levine AJ, Momand J, Finaly CA: The p53 tumour suppressor gene. Nature 1991;351:453-456.
79. Levine AJ: The 1993 Walter Hubert Lecture: The role of the p53 tumour suppressor gene in tumorigenesis. Br J Cancer 1994;69:409-416.
80. Barton CM, Staddon SL, Hughes CM, Hall PA, O'Sullivan C, Klöppel G, Theis B, Russel RCG, Neoptolemos J, Williamson RCN, Lane DP, Lemoine NR: Abnormalities of the p53 tumor suppressor gene in human pancreatic cancer. Br J Cancer 1991;64:1076-1082.
81. Casey G, Yamanaka Y, Friess H, Kobrin MS, Lopez ME, Büchler M, Beger HG, Korc M: p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. Cancer Lett 1993;69:151-160.
82. Diller L, Kassel J, Nelson CE, Gryka MA, Litwak G, Gebhardt M, et al: p53 functions as a cell cycle control protein in osteosarcoma. Mol Cell Biol 1990;10:5772-5781.
83. Yokoyama M, Yamanaka Y, Friess H, Büchler M, Korc M: p53 expression in human pancreatic cancer correlates with enhanced biological aggressiveness. Anticancer Res 1994;14:2477-2484.
84. Grünewald K, Lyons J, Fröhlich A, Feichtinger H, Weger RA, Schwab G, Janssen JWG, Bartram CR: High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas. Int J Cancer 1989;43:1037-1041.
85. Lemoine NR, Jain S, Hughes CM, Staddon SL, Maillet B, Hall PA, Kloppel G: Ki-ras oncogene activation in preinvasive pancreatic cancer. Gastroenterology 1992;102:230-236.
86. Pellegata NS, Sessa F, Renault B, Bonato M, Leone BE, Solcia E, Ranzani GN: K-ras and p53 gene mutations in pancreatic cancer: Ductal and nonductal tumors progress through different genetic lesions. Cancer Res 1994;54:1556-1560.
87. Vogelstein B, Kinzler KW: The multistep nature of cancer. Trends Genet 1993;9:138-141.
88. Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 1990;61:759-767.
89. Friess H, Lu Z, Graber HU, Zimmermann A, Adler G, Korc M, Schmid RM, Büchler MW: Bax, but not bcl-2, influences the prognosis of human pancreatic cancer. Gut, 1998;43:414-421.
90. Friess H, Lu Z, Andren-Sandberg A, Berberat P, Zimmermann A, Adler G, Schmid R, Büchler MW: Moderate activation of the apoptosis inhibitor bcl-xL worsens the prognosis in pancreatic cancer. Ann Surg 1998;228:780-787.
91. Gansauge S, Gansauge F, Yang Y, Muller J, Seufferlein T, Ramadani M, Beger HG: Interleukin 1beta-converting enzyme (caspase-1) is overexpressed in adenocarcinoma of the pancreas. Cancer Res 1998;58:2703-2706.
92. Guo X, Friess H, Graber HU, Kashiwagi M, Zimmermann A, Korc M, Büchler MW: KAI1 expression is up-regulated in early pancreatic cancer and decreased in the presence of metastasis. Cancer Res 1996;56:4876-4880.
93. Friess H, Guo XZ, Berberat P, Graber HU, Zimmermann A, Korc M, Büchler MW: Reduced KAI1 expression in pancreatic cancer is associated with lymph node and distant metastasis. Int J Cancer 1998;79:349-355.
94. Motojima K, Tsunoda T, Kanematsu T, Nagata Y, Urano T, Shiku H: Distinguishing pancreatic carcinoma from other periampullary carcinomas by analysis of mutations in the Kirsten-ras oncogene. Ann Surg 1991;214:657-662.
95. Scarpa A, Capelli P, Zamboni G, Oda T, Mukai K, Bonetti F, Martignoni G, Iacono C, Serio G, Hirohashi S: Neoplasia of the ampulla of Vater. Ki-ras and K mutations. Am J Pathol 1993;142:1163-1172.
96. Scarpa A, Zamboni G, Achille A, Capelli P, Bogina G, Iacono C, Serio G, Accolla RS: ras-family gene mutations in neoplasia of the ampulla of Vater. Int J Cancer 1994;59:39-42.
97. Scarpa A, Pederzoli P, Zamboni G: Genetics of panceratic and periampullary tumors; in Dervenis CG (ed): Advances in Pancreatic Diseases. Stuttgart, Thieme, 1996, pp 2-11.
98. Vaidya P, Kawarada Y, Higashiguchi T, Yoshida T, Sakakura T, Yatani R: Overexpression of different members of the type 1 growth factor receptor family and their association with cell proliferation in periampullary carcinoma. J Pathol 1996;178:140-145.
99. Resnick MB, Gallinger S, Wang HH, Odze RD: Growth factor expression and proliferation kinetics in periampullary neoplasms in familial adenomatous polyposis. Cancer 1995;76:187-194.